Additional data presented at AAD 2025 further cement Bimzelx' leadership in the IL-17 space for PsO and HS. In PsO, efficacy was well maintained from previous 4-year data into the 5-year follow-up with 67.7% PASI100 and 84.9% PASI90. In HS, additional 2-year data saw 55.7% pts with draining tunnels at baseline, a particularly painful manifestation, reaching clearance after two years. We reiterate our confidence in Bimzelx as an rising leader in the dermatology/rheumatology space, and confirm our...
We reiterate our BUY rating on UCB and increase our target price from €212 to €220 on the back of a slight increase in Bimzelx's long-term peak sales and Evenity, which is now profitable in Europe. We continue to view UCB's risk/reward balance as favourable, with the group pipeline accounting for only 6% of Enterprise Value. This allows UCB to have a decade-plus visibility on top- and bottom-line growth, in our view. We believe UCB offers growth at a reasonable valuation, the company now trading...
Aalberts: Dividend and outlook better than expected. Ackermans & van Haaren: Anticipating an all-time-high result from core segments. Ageas: FY24 in line, strong capital, outlook for upsteams. AMG: Strong 4Q24 beat and 2025F guidance upgrade. CFE: Solid results and balance sheet, outlook weak. CMB.TECH: Cautious on outlook. Corbion: Not so sweet. CTP: Good results, 2025 outlook realistic. D'Ieteren: Boyd's Five-Year Goals. Exor: Ferrari €3bn ABB and €1bn SBB. Sofina: Further ...
As UCB accelerates its product launches, revenue growth spikes to € 6.15bn (+19% CER), while 24.0% adj. EBITDA margin came in nicely in line with expectations. We deem FY25 revenue guidance of € 6.5-6.7bn rather cautious, slightly below our and CSS expectations, but still reflecting strong momentum for growth drivers Bimzelx, Zilbrysq, Rystiggo, Fintepla and Evenity. € 214 TP and Accumulate rating reiterated.
Aedifica: Good results, positive message about tenants growth. AGEAS: BNP Paribas increase stake >15% ASR: 2H results and SBB in line, capital strength building up. Belgian Telecoms: Peer Telenet 4Q24 results, guiding for low to mid single digit EBITDAal decline EVS: Exceptional FCF, 2025 EBIT consensus to go up >7% on +10-15% like for like sales growth YoY Gimv: In close cooperation with WorxInvest KPN: VodafoneZiggo 4Q24 still weak, declining EBITDA guidance on “strategic customer initiatives”...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.